Journal article

Urinary hepcidin: an inverse biomarker of acute kidney injury after cardiopulmonary bypass?

John R Prowle, Mark Westerman, Rinaldo Bellomo

Current Opinion in Critical Care | LIPPINCOTT WILLIAMS & WILKINS | Published : 2010

University of Melbourne Researchers


Funding Acknowledgements

Dr M.W. is a shareholder, President and CEO of Intrinsic LifeSciences, developer and distributor of an ELISA assay for hepcidin. Dr J.P. and Professor R.B. are named in a US preliminary patent application in conjunction with Dr M.W. Professor R.B. has received consulting fees from Gambro Biosite, Abbott Diagnostics, and Philips Medical Systems, and grant support from Fresenius Kabi, Bard, Pfizer, and Gambro.